Comparative Pharmacology
Head-to-head clinical analysis: IDAMYCIN versus VALRUBICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDAMYCIN versus VALRUBICIN.
IDAMYCIN vs VALRUBICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idarubicin is an anthracycline antineoplastic agent that intercalates with DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and transcription, and ultimately cell death. It also generates free radicals and induces apoptosis.
Anthracycline topoisomerase II inhibitor and DNA intercalator, causing DNA damage and cell death.
12 mg/m² IV daily for 3 days (acute myeloid leukemia) or 12 mg/m² IV daily for 3 days (acute lymphoblastic leukemia); maximum cumulative dose 600 mg/m².
Intravesical instillation: 800 mg (4 vials of 200 mg/5 mL) diluted in 25 mL of 0.9% Sodium Chloride Injection, instilled into the bladder once weekly for 6 weeks. Retain in bladder for 1-2 hours.
None Documented
None Documented
Clinical Note
moderateValrubicin + Digoxin
"Valrubicin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateValrubicin + Digitoxin
"Valrubicin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateValrubicin + Deslanoside
"Valrubicin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateValrubicin + Acetyldigitoxin
"Valrubicin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 20-30 hours (mean ~22 hours). Prolonged in severe hepatic impairment (up to 40 hours) and may be extended in patients with renal impairment due to accumulation of active metabolite idarubicinol (half-life > 60 hours).
Terminal half-life is approximately 38 hours; clinically, it supports every-3-week dosing to avoid accumulation.
Primarily hepatic metabolism; biliary excretion of metabolites accounts for ~50% of total elimination. Renal excretion of unchanged drug is minimal (<10%). Approximately 30-40% of the dose is recovered in urine as metabolites. Fecal elimination of metabolites accounts for ~50%.
Primarily hepatic metabolism and biliary excretion; renal excretion accounts for <5% of unchanged drug.
Category C
Category C
Anthracycline Antineoplastic
Anthracycline Antineoplastic